نتائج البحث - "Di Giuseppe, Daniela"

المصدر: Provan , S A , Ljung , L , Kristianslund , E K , Michelsen , B , Uhlig , T , Jonmundsson , T , Sexton , J , Gudbjornsson , B , Di Giuseppe , D , Hetland , M L , Reynisdottir , G B , Glintborg , B , Relas , H , Aaltonen , K , Kvien , T K & Askling , J 2024 , ' Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls : Data From 5 Nordic Registries ' , The Journal of rheumatology ....

مصطلحات موضوعية: interstitial lung disease, methotrexate, psoriatic arthritis, rheumatoid arthritis

وصف الملف: application/pdf

الاتاحة: https://researchprofiles.ku.dk/da/publications/interstitial-lung-disease-in-patients-with-rheumatoid-arthritis-or-psoriatic-arthritis-initiating-biologics-and-controls(f084f1b3-d1a6-463d-af12-b262d252bfc4).html
https://doi.org/10.3899/jrheum.2024-0252
https://curis.ku.dk/ws/files/412257622/1111.full.pdf

View record in BASE

13

Academic Journal

Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls : Data From 5 Nordic Registries

المؤلفون: Provan, Sella Aarrestad, Ljung, Lotta, Kristianslund, Eirik Klami, Michelsen, Brigitte, Uhlig, Till, Jonmundsson, Thorarinn, Sexton, Joe, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Hetland, Merete Lund, Reynisdottir, Gudrun Bjork, Glintborg, Bente, Relas, Heikki, Aaltonen, Kalle, Kvien, Tore Kristian, Askling, Johan

المساهمون: HUS Inflammation Center, Reumatologian yksikkö, University of Helsinki

مصطلحات موضوعية: interstitial lung disease, methotrexate, psoriatic arthritis, rheumatoid arthritis, General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: This project was supported by NordForsk; Foreum; Vinnova, Innovationsfonden, and the Research Council of Norway, under the framework of NordForsk (grant agreement no. 90825, Project NORA); and the Swedish Research Council, Innovationsfonden, the Federal Ministry of Education and Research in Germany, and the Research Council of Norway, under the framework of ERA PerMed (Project ScandRA). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the manuscript.SAP reports grants/contracts from Boehringer Ingelheim and Novartis, and payment/honoraria from Pfizer and Boehringer Ingelheim. LL has acted as the principal investigator (PI)-as a registered holder for the SRQ-for agreements during the past 5 years made by the SRQ through Karolinska University Hospital with AbbVie, Amgen, Eli Lilly, Galapagos, Novartis, Pfizer, Sanofi, Sobi, UCB, Janssen, BMS, GSK, and Otsuka. BM reports grants/contracts from Novartis. TU reports payment/honoraria from Galapagos, Lilly, Pfizer, SOBI, and UCB. TJreports consulting fees from Novartis and payment/honoraria from Novartis and Nordic-Pharma. MLH reports grants from or contracts with AbbVie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics BV, Lundbeck Foundations, MSD, Pfizer, Roche, Samsung Biopsies, Sandoz, and Novartis; reports payment/honoraria from Pfizer, Medac, and Sandoz; has chaired the steering committee of the Danish Rheumatolog y Quality (DRQ) Registry (DANBIO), which receives public funding from the hospital owners and funding from pharmaceutical companies; and co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondylorthritis based on secondary data and is partly funded by Novartis. B. Glintborg reports grants from or contracts with BMS, Sandoz, and AbbVie, paid to the University of Copenhagen. HR reports payment/honoraria from UCB, support for attending conferences from Mylan and Janssen, and participation in data monitoring for AbbVie and Pfizer. TKK reports grants from or contracts with AbbVie, BMS, Galapagos, Novartis, Pfizer, and UCB; consulting fees from AbbVie, Gilead, Janssen, Novartis, Pfizer, Sandoz, and UCB; and payment/honoraria from Gruenenthal and Sandoz. JA reports grants from or contracts with AbbVie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, and Sanofi, and agreements between Karolinska Institutet (with JA as PI) and the beforementioned entities, mainly for the national safety monitoring of rheumatolog y immunomodulators in Sweden (ARTIS). The remaining authors declare no conflicts of interest relevant to this article.; http://hdl.handle.net/10138/588604; 85208452376; 001348754700005

الاتاحة: http://hdl.handle.net/10138/588604

View record in BASE

14

Academic Journal

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

المساهمون: HUS Internal Medicine and Rehabilitation, Department of Medicine, Clinicum

مصطلحات موضوعية: General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: Linde , L , Georgiadis , S , Ørnbjerg , L M , Rasmussen , S H , Michelsen , B , Askling , J , Di Giuseppe , D , Wallman , J K , Závada , J , Pavelka , K , Bernardes , M , Matos , C O , Glintborg , B , Loft , A G , Nordström , D , Kuusalo , L , Möller , B , Nissen , M J , Codreanu , C , Mogosan , C , Gudbjornsson , B , Love , T J , Akleylek , C , Iannone , F , Kvien , T K , Rotar , Z , Castrejon , I , Macfarlane , G J , Hetland , M L & Østergaard , M 2024 , ' Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries ' , Arthritis Care and Research . https://doi.org/10.1002/acr.25396; http://hdl.handle.net/10138/585130; 60f2dc52-b093-4fd3-b216-01d853054d71; 85201548710; 001294036300001

الاتاحة: http://hdl.handle.net/10138/585130

View record in BASE

15

Academic Journal

Exposure to antibiotics and risk of latent autoimmune diabetes in adults and type 2 diabetes : results from a Swedish case–control study (ESTRID) and the Norwegian HUNT study

المؤلفون: Edstorp, Jessica, Rossides, Marios, Ahlqvist, Emma, Alfredsson, Lars, Askling, Johan, Di Giuseppe, Daniela, Grill, Valdemar, Sorgjerd, Elin P., Tuomi, Tiinamaija, Åsvold, Bjørn O., Carlsson, Sofia

المساهمون: Centre of Excellence in Complex Disease Genetics, HUS Abdominal Center, Institute for Molecular Medicine Finland, Tiinamaija Tuomi Research Group, Clinicum, University of Helsinki, Endokrinologian yksikkö

مصطلحات موضوعية: Antibacterial agent, Case–control study, Diabetes mellitus, ESTRID, HUNT, LADA, Latent autoimmune diabetes in adults, Registries, Type 2 diabetes, General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: The ESTRID study was funded by grants from the Swedish Research Council (2018-03035), Research Council for Health, Working Life and Welfare (FORTE, 2018-00337), Novo Nordisk Foundation (NNF19OC0057274) and Swedish Diabetes Foundation. The ANDIS study was financed by Swedish governmental funding of clinical research (ALF), the Faculty of Medicine at Lund University, the Swedish Research Council (project grant no. 2020-02191 and strategic research area grant no. 2009-1039 [EXODIAB]), the Swedish Foundation for Strategic Research (IRC15-0067 [LUDC-IRC]) and Vinnova Swelife. EA was also funded by the Novo Nordisk Foundation (grant no. NNF21OC0070457), the Crafoord Foundation, the Bo & Kerstin Hjelt Diabetes Foundation and the Albert P\u00E5hlsson Foundation. The Tr\u00F8ndelag Health Study (HUNT) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Tr\u00F8ndelag County Council, the Central Norway Regional Health Authority and the Norwegian Institute of Public Health.; http://hdl.handle.net/10138/587693; 85207747931; 001344342700001

الاتاحة: http://hdl.handle.net/10138/587693

View record in BASE

16

Academic Journal

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis

المساهمون: HUS Inflammation Center, Reumatologian yksikkö

مصطلحات موضوعية: spondylitis, ankylosing, MTX, SSZ, TNF inhibitors, epidemiology, MODIFYING ANTIRHEUMATIC DRUGS, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, PSORIATIC-ARTHRITIS, TREATMENT RESPONSE, SPONDYLOARTHRITIS, COMEDICATION, INFLIXIMAB, METHOTREXATE, SURVIVAL, General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit.; Nissen , M , Delcoigne , B , Di Giuseppe , D , Jacobsson , L , Hetland , M L , Ciurea , A , Nekvindova , L , Iannone , F , Akkoc , N , Sokka-Isler , T , Fagerli , K M , Santos , M J , Codreanu , C , Pombo-Suarez , M , Rotar , Z , Gudbjornsson , B , Van der Horst-Bruinsma , I , Loft , A G , Moeller , B , Mann , H , Conti , F , Cetin , G Y , Relas , H , Michelsen , B , Ribeiro , P A , Ionescu , R , Sanchez-Piedra , C , Tomsic , M , Geirsson , A J , Askling , J , Glintborg , B & Lindström , U 2022 , ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis ' , Rheumatology , vol. 61 , no. 12 , pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174; http://hdl.handle.net/10138/575581; c92939b4-34dd-46c0-82a7-b041631b3870; 000784112300001

الاتاحة: http://hdl.handle.net/10138/575581

View record in BASE

17

Academic Journal

The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries

المؤلفون: Di Giuseppe, Daniela, Lindström, Ulf, Aaltonen, Kalle, Relas, Heikki, Provan, Sella, Gudbjornsson, Bjorn, Hetland, Merete Lund, Askling, Johan, Kauppi, Markku, Geirsson, Arni Jon, Chatzidionysiou, Katerina, Jørgensen, Tanja Schjødt, Dreyer, Lene, Michelsen, Brigitte, Jacobsson, Lennart T. H., Glintborg, Bente

المساهمون: HUS Inflammation Center, Reumatologian yksikkö, HYKS erva, Päijät-Häme Welfare Consortium

مصطلحات موضوعية: General medicine, internal medicine and other clinical medicine

وصف الملف: application/pdf

Relation: Di Giuseppe , D , Lindström , U , Aaltonen , K , Relas , H , Provan , S , Gudbjornsson , B , Hetland , M L , Askling , J , Kauppi , M , Geirsson , A J , Chatzidionysiou , K , Jørgensen , T S , Dreyer , L , Michelsen , B , Jacobsson , L T H & Glintborg , B 2022 , ' The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries ' , Rheumatology , vol. 61 , no. 9 , keab946 , pp. 3647-3656 . https://doi.org/10.1093/rheumatology/keab946; Bibtex: di2021occurrence; http://hdl.handle.net/10138/575582; ff3eeb88-9711-4e55-b321-059b3f13eb0a; 000756758800001

الاتاحة: http://hdl.handle.net/10138/575582

View record in BASE